Study of VIR-2218 in Patients With Chronic Hepatitis B in Mainland China
Status:
Completed
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
This study is to evaluate the safety, pharmacokinetics characteristics, and antiviral
activities of multiple doses of VIR-2218 in adults with chronic HBV infection in mainland
China.